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ABSTRACT
Objective: Metabolic syndrome changes in different ethnic and age group. Trace elements are associated with metabolic syndrome. The present study 
was aimed to assess the serum levels of iron, zinc, and copper in Gorgan and their association with the metabolic syndrome components.
Methods: The present study was carried out in the Metabolic Disorders Research Center of Gorgan Faculty of Medicine. There were 152 Type 2 diabetic 
subjects who were referred to the Department of Diabetes Center in 5th Azar Educational Hospital in Golestan University of Medical Sciences, Iran, 2014.
Results: The mean waist circumference, systolic blood pressure (SBP) and diastolic blood pressure (DBP), total cholesterol, triglyceride, and 
fasting blood glucose levels were significantly higher in the Type 2 diabetic patients with metabolic syndrome, but the mean HDL-cholesterol was 
significantly lower (p<0.05). Mean serum level of copper was slightly higher, and mean serum level of zinc and iron were lower in patients with 
metabolic syndrome than that of subjects without metabolic syndrome. There were significant differences in the mean of SBP and DBP, triglyceride, 
high-density lipoprotein (HDL)-cholesterol, and fasting blood glucose in men and women with metabolic syndrome when compared with subjects 
without metabolic syndrome. There were also significant differences in the mean of body mass index and waist circumference in women with 
metabolic syndrome. Serum zinc positively correlated with HDL-cholesterol level (in all and in women Type 2 diabetic patients), SBP (in all Type 2 
diabetic patients), and DBP (in men Type 2 diabetic patients) (p<0.05).
Conclusion: Differences of our results with other studies emphasize further research on trace elements and metabolic syndrome and their relationship 
with different diseases are necessary.
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INTRODUCTION
Metabolic syndrome is explained as a cluster of risk factors, which may 
expose subjects to diabetes and cardiovascular diseases [1]. Differences 
in genetic diversities, age, and sex influence the prevalence of metabolic 
syndrome and its components [2]. Studies of Marjani et al. have been 
shown that metabolic syndrome change in different ethnic and age 
groups and postmenopausal women [3-7]. The trace elements such 
as zinc (Zn), copper (Cu), and iron (Fe) are associated with metabolic 
syndrome [8,9]. It has been shown that zinc level is associated with 
total cholesterol and low-density lipoprotein (LDL) cholesterol [8]. 
A  study has indicated that metabolic syndrome is associated with 
the metabolism of zinc [9]. Some other studies have shown that the 
level of zinc changed in different conditions like obesity and Type 2 
diabetic patients as observed in animal and human patterns [10-15]. 
Zinc as a trace element participates in the metabolism of proteins, 
carbohydrates, lipids, and nucleic acids [16,17]. Zinc deficiency may 
cause insulin resistance, hyperglycemia, impaired glucose tolerance [9], 
and the development of diabetes [18]. Studies have indicated that 
zinc trigger lipogenesis and glucose transport in adipocytes of 
rat [19] and glucose uptake in skeletal muscle of mouse [20]. There 
is a relationship between metabolic syndrome and  insulin resistance. 
Another important trace element is iron. Many studies have shown that 
there is a link between insulin resistance and hepatic  iron overload 
(elevated serum ferritin level) [21,22]. Some different studies have 
indicated that there are an association between elevated serum ferritin 
and serum alanine transaminase, hypertension, and myocardial 
infarction, respectively [23-25]. Bozzini et al. showed an association 
between metabolic syndrome and excess of body iron [26]. Evidence 
shows that the accumulation of body iron is related to the metabolic 
syndrome and Type 2 diabetes in general populations [27]. Studies 
on middle-aged or older men and of postmenopausal women have 
revealed that there is an association between iron metabolism and 
disorders of glucose metabolism [28,29]. Many studies have indicated 
that higher iron stores are associated with the progress of diabetes and 
coronary heart disease while lower iron stores decrease the prevalence 
of these diseases [30,31]. Some studies have indicated mildly high 
levels of body iron stores are shown as a risk factor for cardiovascular 
disease [25,32-35]; whereas other study has shown that there was 
no relation between iron level and coronary heart disease [35]. It has 
been reported that there is an association between iron stores and risk 
of diabetes, hepatic damage, and cardiovascular diseases [36]. Few 
studies have shown an  association of trace element levels in subjects 
with or without metabolic syndrome in different populations [37,38] . 
Trace elements take part in metabolism, growth, immunological, and 
neurological functions [39]. Copper is another essential trace element 
that catalyzes oxidation - reduction reactions, detoxification, transport, 
production, and formation reactions [40]. A study has been shown that 
there is a relationship between copper level and total cholesterol, LDL 
cholesterol, and triglyceride levels [41]. Epidemiological studies have 
revealed that there is a positive association between low zinc and 
copper levels and elevated risk of cardiovascular disease [42]. Another 
study has shown an association of copper, zinc, and iron levels and scope 
of myocardial damage [43]. The present study was aimed to assess the 
serum levels of zinc, iron, and copper in Gorgan (South East of Caspian 
Sea) and their association with the metabolic syndrome components 
Type 2 diabetic patients.
METHODS
The present study was carried out in the Metabolic Disorders Research 
Center of Gorgan Faculty of Medicine, Iran in 2014. There were 152 
Type 2 diabetic subjects. All diabetic patients, aged 56.35±3.94 years 
who were referred to the Department of Diabetes Center (the only 
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Diabetes Center in Gorgan) in 5th Azar Educational Hospital in Golestan 
University of Medical Sciences participated in this study, 2014. Subjects 
with chronic liver disease, chronic renal disease, chronic and acute 
infections, recent acute illness, cirrhosis, hyperthyroidism, recent blood 
donation or transfusion, and recent intake of iron therapy were excluded. 
A ten ml venous blood sample was collected from all subjects after 
12 hrs overnight fast. The serum fasting blood glucose, triglycerides, 
LDL-cholesterol, and high-density lipoprotein  (HDL)-cholesterol levels 
were measured by commercial kit using spectrophotometer techniques 
(Model JENWAY 6105 UV/VIS) in the Metabolic Disorders Research 
Center. Weight was measured, while subjects were minimally clothed 
without shoes, using digital scales. Height was measured in standing 
position using tape meter while the shoulder was in a normal position. 
 Body mass index (BMI) was  defined as weight in kilograms divided 
by height in meters squared. Overweight was defined as BMI  25.0-
29.9 kg/m2 and obese as BMI ≥ 30 kg/m2 [44]. Waist circumferences 
were measured at the point halfway between the lower border of 
ribs and the iliac crest in a horizontal plane [45]. Systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) were  measured 
in sitting position on the right hand. Metabolic syndrome identified 
if Type 2 diabetic subjects had any three or more of the following 
criteria, according to the adult treatment Panel III [46]: (1) Abdominal 
obesity: Waist circumference >102 cm in males and >88 cm in females, 
(2) hypertriglyceridemia: Serum triglycerides level ≥ 150 mg/dl, (3) Low 
HDL-cholesterol: < 40 mg/dl in males and < 50 mg/dl in females, 
(4) High blood pressure: SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg or on 
treatment for hypertension, and (5) High fasting glucose: Serum glucose 
level ≥110 mg/dl or on treatment for diabetes. Serum copper, iron, 
and zinc were determined by flame atomic absorption spectrometry 
(Perkin Elmer 560, Norwalk, CT, USA). The results are shown as means 
and standard deviations and percentages. All statistical analysis was 
calculated with SPSS - 16 version software. The results were evaluated by 
using independent sample t-test and Associations between parameters 
were evaluated by Spearman correlation coefficients. A p<0.05 was 
considered as statistically significant.
RESULTS
A total of 152 Type-2 diabetic patients were studied. The mean age of 
the subjects was 56.36±3.94 years. The mean duration of diabetes was 
4.09±1.75 years. Table 1 shows the clinical and biochemical data of the 
subjects with and without the metabolic syndrome in Type 2 diabetic 
patients. The mean waist circumference, SBP and DBP, total cholesterol, 
triglyceride, and fasting blood glucose levels were significantly higher 
in the Type 2 diabetic patients with metabolic syndrome, but the mean 
HDL-cholesterol was significantly lower as (p<0.05). Mean serum level 
of copper was slightly higher, and mean serum level of zinc and iron 
were lower in patients with metabolic syndrome than that of subjects 
without metabolic syndrome. Table 2 shows clinical and biochemical 
data of Type 2 diabetic men and women with and without metabolic 
syndrome. There were significant differences in the mean of SBP and 
DBP, triglyceride, HDL-cholesterol, and fasting blood glucose in men 
and women with metabolic syndrome when compared with subjects 
without metabolic syndrome. There were also significant differences 
in the mean of BMI and waist circumference in women with metabolic 
syndrome. Mean serum level of trace elements in men and women with 
metabolic syndrome were not significant when compared with that of 
subjects without metabolic syndrome. Correlation between serum iron, 
zinc, and copper levels and characteristics of study subjects in Type 2 
diabetic patients, in men and women with the metabolic syndrome, are 
summarized in Tables 3 and 4. Serum zinc positively correlated with 
HDL-cholesterol level (in all and in women Type 2 diabetic patients), 
SBP (in all Type 2 diabetic patients), and DBP (in men Type 2 diabetic 
patients) (p<0.05). There was no significant correlation between copper 
or iron and components of the metabolic syndrome and other subjects.
DISCUSSION
The aim of this study was to assess the association between metabolic 
syndrome and trace elements in Type 2 diabetics. Among Type 2 
diabetic patients with metabolic syndrome, the mean BMI was in the 
range of obesity (BMI>30 kg/m2), the mean triglyceride (209 mg/dl), 
fasting blood glucose (181 mg/dl), and waist circumference (100 cm) 
were above the normal range, and the mean HDL was low 
(33 mg/dl). Serum triglycerides are as risk factors for ischemic heart 
disease [26]. It is one of the components of metabolic syndrome. We 
found no significant association between serum iron concentration 
and metabolic syndrome components. Mean fasting serum iron and 
zinc levels were found to be slightly lower whereas copper level was 
higher in Type 2 diabetic patients with metabolic syndrome than that 
of without metabolic syndrome. A role of iron was for the 1st time 
described by Sullivan in 1981. Iron stores were shown to be decreased 
in women after menopause in comparison with premenopausal iron 
stores [47]. According to our results, all subjects and women with 
metabolic syndrome show lower serum iron level (not significant) 
when compared to those without metabolic syndrome. Serum iron 
level was higher in men. Elevated body iron may show an important 
role in the development of diabetic complications. Increased body iron 
may cause to metabolic abnormalities, which may increase free radicals 
formation. These radicals can take part in oxidative damage and lead to 
diabetic complications development [29,31,48].
Some studies have shown that increased iron level could affect 
insulin synthesis and secretion in the pancreas [49,50]. Increased 
iron also could elevate lipid peroxidation (especially have an effect 
on free fatty acids) which decrease glucose consumption and activate 
gluconeogenesis pathway in the liver. These lead to the development 
of insulin resistance [49,50]. Our study demonstrates that increased 
serum iron in men were not significantly associated with metabolic 
syndrome components in Type 2 diabetic patients. Studies have shown 
that progressive iron accumulation in the pancreatic cell is a disorder 
of glucose tolerance in patients with iron overload [51]. It has been also 
shown that iron metabolism is related to the component of the metabolic 
syndrome [30] which is not in agreement with our results. There was 
significant no correlation between iron and the component of the 
metabolic syndrome, however, a significant correlation was observed 
between zinc and metabolic syndrome components. Many studies 
revealed that metabolic syndrome is associated with elevated body iron 
stores in Western and Eastern countries [27,30,52,53]. Recent studies 
on healthy Chinese women have shown that higher iron stores were 
associated with Type 2 diabetes [54]. Several studies have reported 
the association between iron stores and component of metabolic 
syndrome, including hypertension [25], dyslipidemia [55,56], elevated 
fasting insulin and blood glucose [28], and central obesity [57]. No 
one of these parameters was in line with our findings. Acute zinc 
deficiency is not frequent in diabetic patients while some studies 
have shown that there is a zinc deficiency in Type 2 diabetes [58-61] 
but some other studies were not found significant differences with 
healthy subjects [62,63]. Recent studies indicated decreased levels 
of zinc in obese, insulin-resistant subjects [64]. A decreased zinc 
level seems to have a relationship with elevated risk for coronary 
artery disease [61] and mortality [65]. Some of these studies are in 
agreement with our results [58-61,64]. Copper and zinc are cofactors 
of different antioxidant enzymes. Many studies have revealed that 
there are conflicting results in these trace element levels in subjects 
with or without metabolic syndrome [38,39,65-67]. The present 
study showed that serum zinc was associated with the components 
of metabolic syndrome. A study in Europe indicated that zinc was 
negatively associated with metabolic syndrome components [68]. 
The association between zinc and metabolic syndrome in our study 
are in agreement with the results of other study [68]. Serum copper 
was not associated with the components of metabolic syndrome in 
our findings. The study showed that copper was negatively associated 
with metabolic syndrome components [68]. The lack of association 
between copper and metabolic syndrome in our study subjects are in 
agreement with the results of other study [38,39]. Studies on Chinese 
men with metabolic syndrome have shown that serum zinc levels were 
higher in subjects with metabolic syndrome than in control group, 
which was different to subjects with metabolic syndrome in Western 
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countries [69]. The same study showed that serum Zn and Zn/Cu were 
elevated in metabolic syndrome when compared to subjects without 
metabolic syndrome.
Serum Zn levels were positively correlated with SBP and DBP [69]. 
Another study has indicated that Zn and Zn/Cu were increased in 
study model of a rat with hypertension and low level of serum Cu [70]. 
On the other hand, their conclusion showed that an increased Zn and 
decreased Cu may be involved in higher blood pressure. Some studies 
have shown that there were no association between copper or zinc and 
metabolic syndrome in both genders [67,71]. Our findings showed that 
serum levels of zinc decreased in all, men and women Type 2 diabetic 
patients, which are in agreement with other studies [69-71]. In our 
study, the correlation between serum copper and metabolic syndrome 
components was not seen to reach significant value. In inconsistent to 
our study, a study indicated that the level of serum copper correlated 
negatively with total and LDL cholesterol [72]. Studies have shown that 
small weight loss normalizes the plasma zinc and decreases risk factors 
Table 1: Clinical and biochemical data of Type 2 diabetic subjects with and without metabolic syndrome
Parameters Total number of subjects 
with Type 2 diabetes
Type 2 diabetic subjects 
with metabolic syndrome
Type 2 diabetic subjects 
without metabolic syndrome
P-value
Number of patients (%) 152 (100) 28 (18.42) 124 (81.58)
Age (years) 56.36±3.94 56.38±3.83 56.20±4.45 0.842
Waist circumference (cm) 98.52±11.43 100.36±11.07 90.68±9.63 0.001
Height (cm) 162±0.11 160±0.12 167±0.09 0.005
Weight (kg) 74.83±0.38 75.72±13.65 71.00±12.23 0.074
BMI (kg/m2) 29.20±12.65 30.10±13.83 25.36±3.17 0.001
SBP (mmHg) 130.78±19.48 133.33±1.96 120.0±1.48 0.001
DBP (mmHg) 78.23±12.03 79.35±1.22 73.44±0.97 0.007
Triglyceride (mg/dl) 197.61±84.10 209.99±87.40 144.68±35.51 0.001
Cholesterol (mg/dl) 173.37±50.82 176.65±53.11 159.37±37.16 0.044
HDL-cholesterol (mg/dl) 35.11±10.65 33.15±9.94 43.51±9.55 0.001
LDL-cholesterol (mg/dl) 90.71±47.11 92.65±48.95 82.44±37.93 0.225
Glucose (mg/dl) 171.85±76.80 181.79±77.47 129.34±57.81 0.001
Fe (mg/L) 1.03±0.58 1.01±0.37 1.08±0.62 0.443
Zn (mg/L) 0.94±0.22 0.93±0.22 0.96±0.21 0.506
Cu (mg/L) 1.35±0.38 1.37±0.38 1.26±0.34 0.147
HDL: High-density lipoprotein, LDL: Low-density lipoprotein, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
Table 2: Clinical and biochemical data of Type 2 diabetic men and women with and without metabolic syndrome
Parameters Total number of subjects 
with Type 2 diabetes
Type 2 diabetic subjects 
with metabolic syndrome
Type 2 diabetic subjects 
without metabolic syndrome
p-value
Men
Number of patients (%) 53 (100) 35 (66) 18 (34)
Age (years) 57.33±4.31 57.33±4.31 55.81±3.64 0.869
Waist circumference (cm) 96.90±9.69 99.90±9.69 96.41±12.23 0.229
Height (cm) 170±0.08 170±0.08 157±0.11 0.562
Weight (kg) 78.20±13.49 78.20±13.49 72.98±13.18 0.272
BMI (kg/m2) 26.77±3.62 30.77±3.62 26.53±15.37 0.084
SBP (mmHg) 133.8±1.94 133.8±1.94 129.0±1.93 0.011
DBP (mmHg) 80.1±1.09 80.1±1.09 77.1±1.25 0.040
Triglyceride (mg/dl) 189.12±79.07 202.12±79.07 189.24±86.76 0.006
Cholesterol (mg/dl) 169.61±42.43 175.61±42.43 169.43±54.96 0.258
HDL-cholesterol (mg/dl) 34.61±10.87 34.61±10.87 35.39±10.57 0.01
LDL-cholesterol (mg/dl) 87.44±44.48 92.44±44.48 87.51±48.63 0.836
Glucose (mg/dl) 182.87±81.01 182.87±81.01 165.84±74.13 0.003
Fe (mg/L) 1.03±0.38 1.07±0.38 1.02±0.67 0.745
Zn (mg/L) 0.91±0.16 0.90±0.16 0.98±0.24 0.491
Cu (mg/L) 1.17±0.29 1.27±0.29 1.49±0.41 0.844
Women
Number of patients (%) 99 (100) 89 (89.9) 10 (10.10)
Age (years) 55.81±3.64 56.04±3.69 53.80±2.44 0.749
Waist circumference (cm) 99.41±12.23 101.25±11.14 83.00±9.06 0.001
Height (cm) 157±0.11 157±0.11 158±0.06 0.579
Weight (kg) 72.98±13.18 74.20±13.06 62.20±8.94 0.002
BMI (kg/m2) 30.53±15.37 31.18±16.05 24.75±3.39 0.002
SBP (mmHg) 129.0±1.93 131.3±1.89 109.0±0.99 0.001
DBP (mmHg) 77.1±1.25 78.2±1.24 68.0±0.91 0.007
Triglyceride (mg/dl) 202.24±86.76 209.79±88.14 135.00±20.52 0.009
Cholesterol (mg/dl) 175.43±54.96 177.55±56.66 156.60±32.59 0.098
HDL-cholesterol (mg/dl) 35.39±10.57 34.49±10.44 43.40±8.54 0.010
LDL-cholesterol (mg/dl) 92.51±48.63 94.37±49.92 76.10±32.63 0.137
Glucose (mg/dl) 165.84±74.13 172.22±73.77 109.10±51.48 0.004
Fe (mg/L) 1.02±0.67 1.01±0.69 1.10±0.41 0.422
Zn (mg/L) 0. 95±0.24 0.99±0.23 1.11±0.25 0.073
Cu (mg/L) 1.39±0.41 1.41±0.42 1.34±0.24 0.141
HDL: High-density lipoprotein, LDL: Low-density lipoprotein, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
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for metabolic syndrome. [73]. Low plasma zinc levels were indicated 
in obese [62,63], Type 2 diabetic [18], and obese-Type 2 diabetic 
subjects [15,70]. A study found that there was no statistical correlation 
between plasma zinc and metabolic syndrome components [74]. In this 
study, decrease in serum zinc in patients with metabolic syndrome was 
shown to be negatively correlated with HDL and blood pressure.
CONCLUSION
The results of the study show that only the concentration of zinc 
affected by HDL, SBP, and DBP as components of the metabolic 
syndrome, respectively. There is no relationship between copper and 
iron concentration and metabolic syndrome components. Differences 
of our results with other studies emphasize on further researches on 
trace elements and metabolic syndrome and their relationship with 
different diseases.
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